|
1
|
Singal AG, Kanwal F and Llovet JM: Global
trends in hepatocellular carcinoma epidemiology: Implications for
screening, prevention and therapy. Nat Rev Clin Oncol. 20:864–884.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hwang SY, Danpanichkul P, Agopian V, Mehta
N, Parikh ND, Abou-Alfa GK, Singal AG and Yang JD: Hepatocellular
carcinoma: Updates on epidemiology, surveillance, diagnosis and
treatment. Clin Mol Hepatol. 31:S228–S254. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cheng AL, Qin S, Ikeda M, Galle PR,
Ducreux M, Kim TY, Lim HY, Kudo M, Breder V, Merle P, et al:
Updated efficacy and safety data from IMbrave150: Atezolizumab plus
bevacizumab vs. sorafenib for unresectable hepatocellular
carcinoma. J Hepatol. 76:862–873. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, Li
Q, Lu Y, Chen Y, Guo Y, et al: Sintilimab plus a bevacizumab
biosimilar (IBI305) versus sorafenib in unresectable hepatocellular
carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study.
Lancet Oncol. 22:977–990. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X,
Chen Z, Jia W, Jin Y, Guo Y, et al: Camrelizumab plus rivoceranib
versus sorafenib as first-line therapy for unresectable
hepatocellular carcinoma (CARES-310): A randomised, open-label,
international phase 3 study. Lancet. 402:1133–1146. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hossain MA: A comprehensive review of
immune checkpoint inhibitors for cancer treatment. Int
Immunopharmacol. 143:1133652024. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Barroso-Sousa R, Barry WT, Garrido-Castro
AC, Hodi FS, Min L, Krop IE and Tolaney SM: Incidence of endocrine
dysfunction following the use of different immune checkpoint
inhibitor regimens a systematic review and meta-analysis. JAMA
Oncol. 4:173–182. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hussaini S, Chehade R, Boldt RG, Raphael
J, Blanchette P, Vareki SM and Fernandes R: Association between
immune-related side effects and efficacy and benefit of immune
checkpoint inhibitors-A systematic review and meta-analysis. Cancer
Treat Rev. 92:1021342021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shih YL, Huang YH, Lin KH, Chu YD and Yeh
CT: Identification of functional thyroid stimulating hormone
receptor and TSHR gene mutations in hepatocellular carcinoma.
Anticancer Res. 38:2793–2802. 2018.PubMed/NCBI
|
|
10
|
Liu YC, Yeh CT and Lin KH: Molecular
functions of thyroid hormone signaling in regulation of cancer
progression and anti-apoptosis. Int J Mol Sci. 20:49862019.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lin YH, Lin KH and Yeh CT: Thyroid hormone
in hepatocellular carcinoma: Cancer risk, growth regulation, and
anticancer drug resistance. Front Med. 7:1742020. View Article : Google Scholar
|
|
12
|
Haratani K, Hayashi H, Chiba Y, Kudo K,
Yonesaka K, Kato R, Kaneda H, Hasegawa Y, Tanaka K, Takeda M and
Nakagawa K: Association of immune-related adverse events with
nivolumab efficacy in non-small cell lung cancer. JAMA Oncol.
4:374–378. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yamauchi I, Yasoda A, Matsumoto S,
Sakamori Y, Kim YH, Nomura M, Otsuka A, Yamasaki T, Saito R,
Kitamura M, et al: Incidence, features, and prognosis of
immune-related adverse events involving the thyroid gland induced
by nivolumab. PLoS One. 14:2169542019. View Article : Google Scholar
|
|
14
|
Kotwal A, Kottschade L and Ryder M: PD-L1
inhibitor-induced thyroiditis is associated with better overall
survival in cancer patients. Thyroid. 30:177–184. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu L, Leng C, Chen L, Dong H, Chen Y and
Chen X: Hypothyroidism is a predictive factor of superior
antitumour efficacy of programmed death 1 inhibitors in
hepatocellular carcinoma. Int J Cancer. 150:472–481. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Conrad N, Misra S, Verbakel JY, Verbeke G,
Molenberghs G, Taylor PN, Mason J, Sattar N, McMurray JJV, McInnes
IB, et al: Incidence, prevalence, and co-occurrence of autoimmune
disorders over time and by age, sex, and socioeconomic status: A
population-based cohort study of 22 million individuals in the UK.
Lancet. 401:1878–1890. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hu X, Chen Y, Shen Y, Tian R, Sheng Y and
Que H: Global prevalence and epidemiological trends of Hashimoto's
thyroiditis in adults: A systematic review and meta-analysis. Front
Public Heal. 10:10207092022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Battheu F, Clausi C, Censi S and Mian C:
Differences in autoimmune thyroid diseases between females and
males: The result of a complex interconnection of factors.
Endocrine. 89:665–679. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Concepción-Zavaleta MJ, Coronado-Arroyo
JC, Quiroz-Aldave JE, Concepción-Urteaga LA and Paz-Ibarra J:
Thyroid dysfunction and female infertility. A comprehensive review.
Diabetes Metab Syndr Clin Res Rev. 17:1028762023. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lechner MG, Vyas CM, Hamnvik OPR,
Alexander EK, Larsen PR, Choueiri TK and Angell TE: Risk factors
for new hypothyroidism during tyrosine kinase inhibitor therapy in
advanced nonthyroidal cancer patients. Thyroid. 28:437–444. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tsai K, Ma H, Liang TZ, Xing Y, Chung S,
Dorff T, Bell D and Lechner MG: The combined effect of immune
checkpoint inhibitors and tyrosine kinase inhibitors on thyroid
function. Thyroid. 34:158–166. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kumada T, Toyoda H, Tada T, Yasuda S and
Tanaka J: Changes in background liver function in patients with
hepatocellular carcinoma over 30 years: Comparison of child-pugh
classification and albumin bilirubin grade. Liver Cancer.
9:518–528. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Singer PA, Cooper DS, Levy EG, Ladenson
PW, Braverman LE, Daniels G, Greenspan F, McDougall IR and Nikolai
TF: Treatment guidelines for patients with hyperthyroidism and
hypothyroidism. Standards of Care Committee, American Thyroid
Association. JAMA. 1:35–38. 1995.
|
|
24
|
Cheung YMM, Wang W, McGregor B and Hamnvik
OPR: Associations between immune-related thyroid dysfunction and
efficacy of immune checkpoint inhibitors: A systematic review and
meta-analysis. Cancer Immunol Immunother. 71:1795–1812. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lechner MG, Vyas CM, Hamnvik OPR,
Alexander EK, Larsen PR, Choueiri TK and Angell TE: Hypothyroidism
during tyrosine kinase inhibitor therapy is associated with longer
survival in patients with advanced nonthyroidal cancers. Thyroid.
28:445–453. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen Y, Zhuang L, Zhang D, Du X and Sheng
L: Thyroid dysfunction as a predictive indicator in camrelizumab of
advanced esophageal squamous cell carcinoma. J Immunol Res.
2022:40158972022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Okada N, Iwama S, Okuji T, Kobayashi T,
Yasuda Y, Wada E, Onoue T, Goto M, Sugiyama M, Tsunekawa T, et al:
Anti-thyroid antibodies and thyroid echo pattern at baseline as
risk factors for thyroid dysfunction induced by anti-programmed
cell death-1 antibodies: a prospective study. Br J Cancer.
122:771–777. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kudo M, Ikeda M, Zhu AX, Qin S, Kim TY,
Lim HY, Brede V, Merle P, Kaseb A, Li D, et al: 169P IMbrave150:
Management of adverse events of special interest (AESIs) for
atezolizumab (atezo) and bevacizumab (bev) in unresectable HCC. Ann
Oncol. 31:S1304–S1305. 2020. View Article : Google Scholar
|
|
29
|
Sunder SS, Sharma UC and Pokharel S:
Adverse effects of tyrosine kinase inhibitors in cancer therapy:
Pathophysiology, mechanisms and clinical management. Signal
Transduct Target Ther. 8:2622023. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu J and Huang H: Acquired hypothyroidism
in patients with metastatic renal cell carcinoma treated with
tyrosine kinase inhibitors. Drug Des Devel Ther. 14:3977–3982.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sbardella E, Tenuta M, Sirgiovanni G,
Gianfrilli D, Pozza C, Venneri MA, Cortesi E, Marchetti P, Lenzi A,
Gelibter AJ and Isidori AM: Thyroid disorders in programmed death 1
inhibitor-treated patients: Is previous therapy with tyrosine
kinase inhibitors a predisposing factor? Clin Endocrinol (Oxf).
92:258–265. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rizza L, Sbardella E, Gianfrilli D,
Lauretta R, Tenuta M, Del Bene G, Longo F, Faggiano A, Lenzi A,
Giannetta E and Pozza C: Thyroid profile during the alternative
Sunitinib dosing 2/1 schedule in metastatic renal cell carcinoma.
Endocrine. 67:597–604. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jiao Y, Xu M and Rao X: Correlation
between different levels of thyroid autoantibodies and immune
checkpoint inhibitor-associated thyroid dysfunction. Front
Endocrinol. 13:16207182025. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhou X, Iwama S, Kobayashi T, Ando M and
Arima H: Risk of thyroid dysfunction in PD-1 blockade is stratified
by the pattern of TgAb and TPOAb positivity at baseline. J Clin
Endocrinol Metab. 18:e1056–e1062. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang Q, Jiao X and Lai X: Clinical
characters and influence factors of immune checkpoint inhibitor
related thyroid dysfunction. J Clin Endocrinol Metab.
108:2916–2923. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Guaraldi F, La Selva R, Samà MT, D'Angelo
V, Gori D, Fava P, Fierro MT, Savoia P and Arvat E:
Characterization and implications of thyroid dysfunction induced by
immune checkpoint inhibitors in real-life clinical practice: A
long-term prospective study from a referral institution. J
Endocrinol Invest. 41:549–556. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Delivanis DA, Gustafson MP, Bornschlegl S,
Merten MM, Kottschade L, Withers S, Dietz AB and Ryder M:
Pembrolizumab-induced thyroiditis: Comprehensive clinical review
and insights into underlying involved mechanisms. J Clin Endocrinol
Metab. 102:2770–2780. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Maekura T, Naito M, Tahara M, Ikegami N,
Kimura Y, Sonobe S, Kobayashi T, Tsuji T, Minomo S and Atagi S:
Predictive factors of nivolumab-induced hypothyroidism in patients
with non-small cell lung cancer. In Vivo (Brooklyn). 31:1035–1039.
2017.
|
|
39
|
Weinmann SC and Pisetsky DS: Mechanisms of
immune-related adverse events during the treatment of cancer with
immune checkpoint inhibitors. Rheumatol (Oxford). (Suppl
7):58:vii59–vii67. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wright JJ, Powers AC and Johnson DB:
Endocrine toxicities of immune checkpoint inhibitors. Nat Rev
Endocrinol. 17:389–399. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kegasawa T, Sakamori R, Maesaka K, Yamada
R, Tahata Y, Urabe A, Kodama T, Hikita H, Imanaka K, Ohkawa K, et
al: Lower serum sodium levels are associated with the therapeutic
effect of sorafenib on hepatocellular carcinoma. Dig Dis Sci.
66:1720–1729. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yoon JH, Hong AR, Kim HK and Kang HC:
Characteristics of immune-related thyroid adverse events in
patients treated with PD-1/PD-L1 inhibitors. Endocrinol Metab.
36:413–423. 2021. View Article : Google Scholar : PubMed/NCBI
|
